Rolling Out CT-132 Lessons and Opportunities in Migraine Care: Stewart Tepper, MD

Author(s):

Key Takeaways

CT-132, a digital therapeutic app, is FDA-approved for episodic migraine, integrating cognitive behavioral therapy techniques over 12 weeks.
The app is intended for adjunctive use with other migraine treatments, supported by data from ReMMi-D and ReMMiD-C trials.
Stewart Tepper highlights the need for increased awareness and education about digital therapeutics among clinicians and patients.
Optimism exists for future studies in chronic migraine, leveraging the platform's strong clinical foundations.

The professor of neurology at the Geisel School of Medicine at Dartmouth discussed the clinical rollout of CT-132, a newly FDA-approved digital therapeutic for migraine, and the educational needs facing the neurology community. [WATCH TIME: 4 minutes]

WATCH TIME: 4 minutes

"The additional drop in monthly migraine days and the improvements in patient-reported outcomes, without added side effects, make this a very dramatic advance."

Episodic migraine is a common neurological condition affecting a significant portion of the global population. It is estimated that 12-15% of adults experience migraine headaches, with the majority of these being episodic. Earlier this month, the FDA approved a new therapeutic, CT-132 (Click Therapeutics), as the first digitally-based prescription treatment for adults with episodic migraine, marking a significant milestone for the migraine community.

CT-132, an app-based intervention, integrates multiple evidence-based behavioral techniques, including elements of cognitive behavioral therapy, over a 12-week period. It is indicated for patients aged 18 years and older, intended for adjunctive use alongside acute and/or other preventive treatments for migraine. For context, data from 2, double-blind, decentralized randomized trials, ReMMi-D (NCT05853900) and ReMMiD-C (NCT06004388), served as the basis for the approval.

As the clinical community welcomes this new medication, NeurologyLive^® sat down with migraine expert Stewart Tepper, MD, to discuss the considerations amid its rollout, and what clinicians and patients should understand going forward. Tepper, a professor of neurology at the Geisel School of Medicine at Dartmouth, spoke on the lack of awareness surrounding digital therapeutics, underscoring efforts to accelerate education through publications, CME activities, and professional society initiatives. In addition, he noted that while no new trials are underway yet, Tepper expressed optimism about future studies, particularly in chronic migraine, guided by the platform’s strong clinical foundations.

REFERENCE
1. Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States. News release. Click Therapeutics. April 15, 2025. Accessed April 28, 2025. https://www.biospace.com/press-releases/click-therapeutics-announces-fda-marketing-authorization-for-ct-132-the-first-prescription-digital-therapeutic-for-the-preventive-treatment-of-episodic-migraine-in-the-united-states